Annual CFO
-$22.61 M
+$3.63 M+13.84%
31 December 2023
Summary:
BioLineRx annual cash flow from operations is currently -$22.61 million, with the most recent change of +$3.63 million (+13.84%) on 31 December 2023. During the last 3 years, it has risen by +$598.00 thousand (+2.58%). BLRX annual CFO is now -297.22% below its all-time high of $11.46 million, reached on 31 December 2010.BLRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$9.82 M
+$1.50 M+13.28%
30 September 2024
Summary:
BioLineRx quarterly cash flow from operations is currently -$9.82 million, with the most recent change of +$1.50 million (+13.28%) on 30 September 2024. Over the past year, it has increased by +$76.00 thousand (+0.77%). BLRX quarterly CFO is now -154.13% below its all-time high of $18.15 million, reached on 30 September 2010.BLRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$30.27 M
+$76.00 K+0.25%
30 September 2024
Summary:
BioLineRx TTM cash flow from operations is currently -$30.27 million, with the most recent change of +$76.00 thousand (+0.25%) on 30 September 2024. Over the past year, it has increased by +$3.01 million (+9.04%). BLRX TTM CFO is now -327.00% below its all-time high of $13.34 million, reached on 30 September 2010.BLRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BLRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.8% | +0.8% | +9.0% |
| 3 y3 years | +2.6% | -96.0% | -28.8% |
| 5 y5 years | +6.5% | -59.3% | -35.3% |
BLRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +13.8% | -296.9% | +30.4% | -35.2% | +9.0% |
| 5 y | 5 years | at high | +13.8% | -296.9% | +30.4% | -35.3% | +9.0% |
| alltime | all time | -297.2% | +13.8% | -154.1% | +30.4% | -327.0% | +9.0% |
BioLineRx Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.82 M(-13.3%) | -$30.27 M(-0.3%) |
| June 2024 | - | -$11.33 M(-19.7%) | -$30.35 M(+5.7%) |
| Mar 2024 | - | -$14.11 M(-382.7%) | -$28.70 M(+27.0%) |
| Dec 2023 | -$22.61 M(-13.8%) | $4.99 M(-150.4%) | -$22.61 M(-32.1%) |
| Sept 2023 | - | -$9.90 M(+2.3%) | -$33.28 M(+3.8%) |
| June 2023 | - | -$9.68 M(+20.8%) | -$32.06 M(+11.8%) |
| Mar 2023 | - | -$8.02 M(+41.1%) | -$28.67 M(+9.3%) |
| Dec 2022 | -$26.24 M(+11.3%) | -$5.68 M(-34.5%) | -$26.24 M(+0.7%) |
| Sept 2022 | - | -$8.68 M(+38.1%) | -$26.06 M(+16.4%) |
| June 2022 | - | -$6.29 M(+12.6%) | -$22.39 M(-2.4%) |
| Mar 2022 | - | -$5.59 M(+1.5%) | -$22.93 M(-2.7%) |
| Dec 2021 | -$23.57 M(+1.6%) | -$5.50 M(+9.8%) | -$23.57 M(+0.3%) |
| Sept 2021 | - | -$5.01 M(-26.6%) | -$23.50 M(-1.9%) |
| June 2021 | - | -$6.83 M(+9.6%) | -$23.96 M(+5.6%) |
| Mar 2021 | - | -$6.23 M(+14.7%) | -$22.70 M(-2.2%) |
| Dec 2020 | -$23.21 M(+2.4%) | -$5.43 M(-0.7%) | -$23.21 M(+0.0%) |
| Sept 2020 | - | -$5.47 M(-1.7%) | -$23.20 M(-2.9%) |
| June 2020 | - | -$5.57 M(-17.4%) | -$23.90 M(-3.6%) |
| Mar 2020 | - | -$6.74 M(+24.1%) | -$24.78 M(+9.3%) |
| Dec 2019 | -$22.67 M(-6.3%) | -$5.43 M(-12.0%) | -$22.67 M(+1.3%) |
| Sept 2019 | - | -$6.17 M(-4.3%) | -$22.38 M(+0.7%) |
| June 2019 | - | -$6.45 M(+39.4%) | -$22.22 M(+1.0%) |
| Mar 2019 | - | -$4.62 M(-10.1%) | -$22.01 M(-9.0%) |
| Dec 2018 | -$24.19 M(+17.7%) | -$5.14 M(-14.5%) | -$24.19 M(-4.7%) |
| Sept 2018 | - | -$6.01 M(-3.6%) | -$25.38 M(-0.8%) |
| June 2018 | - | -$6.23 M(-8.4%) | -$25.58 M(+8.6%) |
| Mar 2018 | - | -$6.81 M(+7.6%) | -$23.56 M(+14.7%) |
| Dec 2017 | -$20.55 M | -$6.32 M(+1.7%) | -$20.55 M(+12.2%) |
| Sept 2017 | - | -$6.22 M(+47.6%) | -$18.31 M(+21.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | -$4.21 M(+11.1%) | -$15.07 M(+6.7%) |
| Mar 2017 | - | -$3.79 M(-7.1%) | -$14.12 M(-2.7%) |
| Dec 2016 | -$14.51 M(+2.4%) | -$4.08 M(+37.0%) | -$14.51 M(+6.6%) |
| Sept 2016 | - | -$2.98 M(-8.6%) | -$13.62 M(-5.9%) |
| June 2016 | - | -$3.26 M(-22.0%) | -$14.47 M(-2.8%) |
| Mar 2016 | - | -$4.18 M(+31.2%) | -$14.88 M(+5.1%) |
| Dec 2015 | -$14.17 M(-10.0%) | -$3.19 M(-16.9%) | -$14.17 M(-10.1%) |
| Sept 2015 | - | -$3.83 M(+4.3%) | -$15.75 M(+3.9%) |
| June 2015 | - | -$3.68 M(+6.0%) | -$15.16 M(-4.2%) |
| Mar 2015 | - | -$3.47 M(-27.3%) | -$15.83 M(+0.5%) |
| Dec 2014 | -$15.75 M(-19.3%) | -$4.77 M(+47.1%) | -$15.75 M(+6.2%) |
| Sept 2014 | - | -$3.24 M(-25.3%) | -$14.83 M(-6.5%) |
| June 2014 | - | -$4.34 M(+28.0%) | -$15.87 M(-10.1%) |
| Mar 2014 | - | -$3.39 M(-12.0%) | -$17.66 M(-9.5%) |
| Dec 2013 | -$19.52 M(-2.9%) | -$3.85 M(-10.0%) | -$19.52 M(-13.0%) |
| Sept 2013 | - | -$4.28 M(-30.2%) | -$22.44 M(+1.1%) |
| June 2013 | - | -$6.13 M(+16.8%) | -$22.19 M(+1.4%) |
| Mar 2013 | - | -$5.25 M(-22.4%) | -$21.89 M(+8.8%) |
| Dec 2012 | -$20.11 M(+79.2%) | -$6.77 M(+67.7%) | -$20.11 M(+15.7%) |
| Sept 2012 | - | -$4.04 M(-30.8%) | -$17.39 M(+21.4%) |
| June 2012 | - | -$5.83 M(+67.6%) | -$14.32 M(+16.5%) |
| Mar 2012 | - | -$3.48 M(-13.9%) | -$12.29 M(+9.5%) |
| Dec 2011 | -$11.22 M(-197.9%) | -$4.04 M(+317.4%) | -$11.22 M(+23.9%) |
| Sept 2011 | - | -$967.90 K(-74.6%) | -$9.05 M(-190.0%) |
| June 2011 | - | -$3.81 M(+58.2%) | $10.06 M(-15.5%) |
| Mar 2011 | - | -$2.41 M(+28.5%) | $11.91 M(+3.9%) |
| Dec 2010 | $11.46 M | -$1.87 M(-110.3%) | $11.46 M(-14.0%) |
| Sept 2010 | - | $18.15 M(-1024.9%) | $13.34 M(-377.0%) |
| June 2010 | - | -$1.96 M(-31.2%) | -$4.81 M(+68.8%) |
| Mar 2010 | - | -$2.85 M | -$2.85 M |
FAQ
- What is BioLineRx annual cash flow from operations?
- What is the all time high annual CFO for BioLineRx?
- What is BioLineRx annual CFO year-on-year change?
- What is BioLineRx quarterly cash flow from operations?
- What is the all time high quarterly CFO for BioLineRx?
- What is BioLineRx quarterly CFO year-on-year change?
- What is BioLineRx TTM cash flow from operations?
- What is the all time high TTM CFO for BioLineRx?
- What is BioLineRx TTM CFO year-on-year change?
What is BioLineRx annual cash flow from operations?
The current annual CFO of BLRX is -$22.61 M
What is the all time high annual CFO for BioLineRx?
BioLineRx all-time high annual cash flow from operations is $11.46 M
What is BioLineRx annual CFO year-on-year change?
Over the past year, BLRX annual cash flow from operations has changed by +$3.63 M (+13.84%)
What is BioLineRx quarterly cash flow from operations?
The current quarterly CFO of BLRX is -$9.82 M
What is the all time high quarterly CFO for BioLineRx?
BioLineRx all-time high quarterly cash flow from operations is $18.15 M
What is BioLineRx quarterly CFO year-on-year change?
Over the past year, BLRX quarterly cash flow from operations has changed by +$76.00 K (+0.77%)
What is BioLineRx TTM cash flow from operations?
The current TTM CFO of BLRX is -$30.27 M
What is the all time high TTM CFO for BioLineRx?
BioLineRx all-time high TTM cash flow from operations is $13.34 M
What is BioLineRx TTM CFO year-on-year change?
Over the past year, BLRX TTM cash flow from operations has changed by +$3.01 M (+9.04%)